Company / R&D per Share
Biogen R&D per Share History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D per Share
$12.27
FY2025
5-year range
$12.27 / $16.64
FY2021-FY2025
Trend
-10.7%
vs FY2024
Sector context
#13 of 207
Health Care
What the data says
Among 207 Health Care companies, Biogen is in the top 6% for r&d per share. R&D per Share has fluctuated over the past 10 years, ranging from $9.03 in FY2016 to $20.24 in FY2020.
Based on SEC 10-K filings.
12.27 in FY2025 with a 5-year CAGR of -9.5%. Top quartile in the Health Care sector.
Declined from $16.64 to $12.27 over the past 2 years.
Health Care sector context is included.
R&D per Share over time
Growth rates
- 3-Year CAGR
- -5.7%
- 5-Year CAGR
- -9.5%
- 10-Year CAGR
- -
Sector benchmark
In line with sector averageTop 6% of 207This company $12.27 Sector average $12.26
▼
In line with sector average
Key checks
Key Insights
- In FY2025, r&d per share decreased 10.7% year-over-year.
- Ranks #13 out of 207 companies in the Health Care sector.
- Peak r&d per share was recorded in FY2020.
- Lowest r&d per share in the period was in FY2016.
Company context
Key Data Points
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $12.27 | -10.7% |
| FY2024 | $13.75 | -17.3% |
| FY2023 | $16.64 | +13.6% |
| FY2022 | $14.64 | +2.0% |
| FY2021 | $14.36 | -29.1% |
| FY2020 | $20.24 | +87.7% |
| FY2019 | $10.78 | -10.4% |
| FY2018 | $12.03 | +15.2% |
| FY2017 | $10.44 | +15.6% |
| FY2016 | $9.03 | +5.2% |
As of FY2025 · SEC 10-K · Updated Mar 3, 2026